Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 4;20:1063. doi: 10.1186/s12885-020-07500-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — a Flow cytometry gating strategy for detecting presence of human immune cells in blood of hu-CB-BRGS mice 16 weeks post engraftment and prior to tumor cell inoculation. b Percentage of human CD45+ cells in blood of hu-CB-BRGS mice plotted according to their distribution into treatment groups. c Tumor growth curves of MDA-MB-231 TNBC cell line xenograft tumors in hu-CB-BRGS mice at the indicated doses. Vehicle, Nivo, and RX-5902 arms were ended at Day 26 due to tumor size limits. Treatment was continued for the Combo arm due to their increased survival compared to the other groups. d Percent tumor growth inhibition (%TGI) for the indicated treatment groups. e Tumor growth rates for individual tumors in the indicated treatment groups over the duration of the treatment time. ****p < 0.0001; ***p < 0.001; *p < 0.05